The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...

Gutting USAID is already having a devastating impact around the world. In the Democratic Republic of Congo, teams that would ...

The US regulator has started a priority review of the injectable formulation of HIV-1 capsid inhibitor lenacapavir, which also has breakthrough status, and is due to deliver a decision on the ...

2024 — Recent results from a recent clinical trial indicate that a twice-yearly injection of Lenacapavir offers an overall 96% reduced risk of acquiring ... HIV Latency Reversing Properties in ...